ClinicalTrialsFinder

EGFR Mutated Non-small Cell Lung Cancer Patients Clinical Trials in Boston, Massachusetts

1 recruitingBoston, Massachusetts

Showing 1–1 of 1 trials

Recruiting
Phase 1

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients
Nuvectis Pharma, Inc.18 enrolled3 locationsNCT07315113